Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
22 January, 2018 04:02 IST
Zydus receives USFDAs final nod for Eletriptan HCl tablets
Source: IRIS | 19 Jun, 2017, 10.32AM
Comments  |  Post Comment

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Eletriptan Hydrobromide Tablets, 20 mg (base) and 40 mg (base).

The drug which is used in the treatment of migraine will be produced at the group’s formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 120 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 7.15, or 1.36%, to trade at Rs 532.55. The total volume of shares traded was 33,144 at the BSE (10.24 a.m., Monday).



Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Reliance Q3 profit up 25.5%; GRM at USD 11.6/bbl - 19-Jan-2018 18:34
HDFC Bank Q3 net grows 20% to Rs 41.51 bn - 19-Jan-2018 18:07
Wipro Q3 earnings fall 12% q-o-q to Rs 19.3 bn - 19-Jan-2018 17:56
Lupin launches generic Vibra-Tabs tablet in US - 19-Jan-2018 15:56
HCL Tech Q3 profit jumps 6% to Rs 21.94 bn - 19-Jan-2018 11:45
Suven Life Sciences secures 2 overseas product patents - 18-Jan-2018 15:26
Yes Bank Q3 profit rises 22% to Rs 10.76 bn - 18-Jan-2018 15:24
Sanghvi Forging & Engg bags new orders worth Rs 110 mn - 18-Jan-2018 10:17
Tata Consultancy Services expands partnership with Shure Inc - 18-Jan-2018 10:13
Ashok Leyland signs Lol with Phinergy, Israel for high energy EV - 17-Jan-2018 16:20
Transformers & Rectifiers India receives Rs 1.26 bn order - 17-Jan-2018 16:05
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer